Recombinant
RabMAb

Anti-Integrin beta 3 antibody [ERP17507] (ab179473)

Overview

  • Product name
    Anti-Integrin beta 3 antibody [ERP17507]
    See all Integrin beta 3 primary antibodies
  • Description
    Rabbit monoclonal [ERP17507] to Integrin beta 3
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human Integrin alpha V beta 3 aa 100-400. The exact sequence is proprietary.
    Database link: P05106

  • Positive control
    • WB: HT-29, HEK-293, HUVEC, HeLa and HEL 92.1.7 whole cell lysates; Human spleen lysate; Human plasma. IHC-P: Human spleen, osteosarcomas and thyroid cancer tissues. IP: HeLa whole cell lysate.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab179473 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 130, 97 kDa (predicted molecular weight: 87 kDa).
IHC-P 1/800. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
IP 1/40.

Target

  • Function
    Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Tissue specificity
    Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.
  • Involvement in disease
    Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.
  • Sequence similarities
    Belongs to the integrin beta chain family.
    Contains 1 VWFA domain.
  • Post-translational
    modifications
    Phosphorylated on tyrosine residues in response to thrombin-induced platelet aggregation. Probably involved in outside-in signaling. A peptide (AA 740-762) is capable of binding GRB2 only when both Tyr-773 and Tyr-785 are phosphorylated. Phosphorylation of Thr-779 inhibits SHC binding.
  • Cellular localization
    Membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • BDPLT16 antibody
    • BDPLT2 antibody
    • CD 61 antibody
    • CD61 antibody
    • CD61 antigen antibody
    • GP3A antibody
    • GPIIIa antibody
    • GT antibody
    • HPA 1 antibody
    • HPA 4 antibody
    • Integrin beta 3 (platelet glycoprotein IIIa antigen CD61) antibody
    • Integrin beta chain beta 3 antibody
    • Integrin beta-3 antibody
    • ITB3_HUMAN antibody
    • ITG B3 antibody
    • ITGB 3 antibody
    • ITGB3 antibody
    • NAIT antibody
    • Platelet fibrinogen receptor beta subunit antibody
    • Platelet fibrinogen receptor, beta subunit antibody
    • Platelet glycoprotein IIIa antibody
    • Platelet glycoprotein IIIa precursor antibody
    • Platelet membrane glycoprotein IIIa antibody
    • PTP antibody
    see all

Images

  • All lanes : Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1/1000 dilution

    Lane 1 : HT-29 (Human colorectal adenocarcinoma cell line) whole cell lysate
    Lane 2 : HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate
    Lane 3 : Human spleen lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

    Predicted band size: 87 kDa
    Observed band size: 130,97 kDa (why is the actual band size different from the predicted?)


    Exposure time: 15 seconds


    Blocking/Dilution buffer: 5% NFDM/TBST.

    The molecular weight observed is consistent with the description in the literature (PMID: 1710517).

  • All lanes : Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1/1000 dilution

    Lane 1 : HUVEC (Human umbilical vein endothelial cell line) whole cell lysate
    Lane 2 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

    Predicted band size: 87 kDa
    Observed band size: 130 kDa (why is the actual band size different from the predicted?)


    Exposure time: 10 seconds


    Blocking/Dilution buffer: 5% NFDM/TBST.

    The molecular weight observed is consistent with the description in the literature (PMID: 1710517).

  • Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1000 cells + HEL 92.1.7 (Human bone marrow erythroleukemia cell line) whole cell lysate at 10 µg

    Secondary
    Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution

    Predicted band size: 87 kDa
    Observed band size: 97 kDa (why is the actual band size different from the predicted?)


    Exposure time: 5 seconds


    Blocking/Dilution buffer: 5% NFDM/TBST.

    The molecular weight observed is consistent with the description in the literature (PMID: 1710517).

  • Anti-Integrin beta 3 antibody [ERP17507] (ab179473) at 1/5000 dilution + Human plasma at 10 µg

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size: 87 kDa
    Observed band size: 97 kDa (why is the actual band size different from the predicted?)


    Exposure time: 3 minutes


    Blocking/Dilution buffer: 5% NFDM/TBST.

    The molecular weight observed is consistent with the description in the literature (PMID: 1710517).

  • Immunohistochemical analysis of paraffin-embedded Human spleen tissue labeling Integrin beta 3 with ab179473 at 1/800 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

    Positive staining on platelets (PMID: 25356112) of Human spleen is observed.

    Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is ab97051 at 1/500 dilution.

  • Immunohistochemical analysis of paraffin-embedded Human osteosarcomas tissue labeling Integrin beta 3 with ab179473 at 1/800 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

    Membrane staining on cells of Human osteosarcomas is observed; several multinucleated osteoclasts are positively stained (PMID: 15692727; PMID: 25534583).

    Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is ab97051 at 1/500 dilution.

  • Immunohistochemical analysis of paraffin-embedded Human thyroid cancer tissue labeling Integrin beta 3 with ab179473 at 1/800 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.

    Membrane or cytoplasmic staining on tumor cells of Human thyroid cancer is observed.

    Counter stained with Hematoxylin.

    Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is ab97051 at 1/500 dilution.

  • Integrin beta 3 was immunoprecipitated from 1mg of HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate with ab179473 at 1/40 dilution.

    Western blot was performed from the immunoprecipitate using ab179473 at 1/1000 dilution.

    VeriBlot for IP secondary antibody (HRP) (ab131366), was used as secondary antibody at 1/10000 dilution.

    Lane 1: HeLa whole cell lysate, 10µg (Input).

    Lane 2: ab179473 IP in HeLa whole cell lysate.

    Lane 3: Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) instead of ab179473 in HeLa whole cell lysate.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 3 seconds.

References

ab179473 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab179473.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up